Molecular imaging using PET for breast cancer.

Hiroaki Kurihara, Chikako Shimizu, Yasuji Miyakita, Masayuki Yoshida, Akinobu Hamada, Yousuke Kanayama, Kan Yonemori, Jun Hashimoto, Hitomi Tani, Makoto Kodaira, Mayu Yunokawa, Harukaze Yamamoto, Yasuyoshi Watanabe, Yasuhiro Fujiwara, Kenji Tamura

Journal: Breast cancer (Tokyo, Japan) 2016;23(1):24-32

PMID: 25917108

Full Text on Springer View on PubMed

Abstract

Molecular imaging can visualize the biological processes at the molecular and cellular levels in vivo using certain tracers for specific molecular targets. Molecular imaging of breast cancer can be performed with various imaging modalities, however, positron emission tomography (PET) is a sensitive and non-invasive molecular imaging technology and this review will focus on PET molecular imaging of breast cancer, such as FDG-PET, FLT-PET, hormone receptor PET, and anti-HER2 PET.

Address: Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. [email protected].; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Neurosurgery, National Cancer Center Hospital, Tokyo, Japan.; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.; Department of Clinical Pharmacology Group for Translational Research Support Core, National Cancer Center Research Institute, Tokyo, Japan.; RIKEN Center for Molecular Imaging Science, Kobe, Hyogo, Japan.; Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

DOI: 10.1007/s12282-015-0613-z